XML 34 R24.htm IDEA: XBRL DOCUMENT
v3.25.1

Revenue (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
| Three Months Ended March 31, |  |
| 2025 |  | 2024 |  |  |  |
Net product revenue | $ | 11,601.2 |  |  | $ | 7,796.5 |  |  |  |  |
Collaboration and other revenue | 1,127.3 |  |  | 971.5 |  |  |  |  |
Revenue | $ | 12,728.5 |  |  | $ | 8,768.0 |  |  |  |  |
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:
| Three Months Ended March 31,
| 2025 |  | 2024
| U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total
Cardiometabolic Health: |  |  |  |  |  |  |
Mounjaro | $ | 2,655.9 |  | $ | 1,185.9 |  | $ | 3,841.8 |  |  | $ | 1,520.4 |  | $ | 286.2 |  | $ | 1,806.5 |
Zepbound | 2,305.4 |  | 6.5 |  | 2,311.9 |  |  | 517.4 |  | — |  | 517.4 |
Trulicity | 770.5 |  | 324.7 |  | 1,095.2 |  |  | 1,081.9 |  | 374.4 |  | 1,456.3 |
Jardiance(1) | 309.8 |  | 704.6 |  | 1,014.4 |  |  | 368.2 |  | 318.3 |  | 686.5 |
Other cardiometabolic health | 535.1 |  | 409.7 |  | 944.8 |  |  | 602.1 |  | 424.1 |  | 1,026.3 |
Total cardiometabolic health | 6,576.7 |  | 2,631.4 |  | 9,208.1 |  |  | 4,090.0 |  | 1,403.0 |  | 5,493.0 |
Oncology: |  |  |  |  |  |  |
Verzenio | 657.6 |  | 501.3 |  | 1,158.9 |  |  | 638.2 |  | 412.1 |  | 1,050.3 |
Other oncology | 388.2 |  | 400.4 |  | 788.6 |  |  | 360.1 |  | 399.6 |  | 759.7 |
Total oncology | 1,045.8 |  | 901.7 |  | 1,947.5 |  |  | 998.3 |  | 811.7 |  | 1,810.0 |
Immunology: |  |  |  |  |  |  |
Taltz | 476.5 |  | 285.4 |  | 761.9 |  |  | 347.1 |  | 257.0 |  | 604.1 |
Other immunology | 101.6 |  | 224.6 |  | 326.1 |  |  | 50.1 |  | 179.8 |  | 229.9 |
Total immunology | 578.1 |  | 510.0 |  | 1,088.0 |  |  | 397.2 |  | 436.8 |  | 834.0 |
Neuroscience | 189.3 |  | 82.8 |  | 272.1 |  |  | 163.2 |  | 225.9 |  | 389.1 |
Other | 99.5 |  | 113.3 |  | 212.9 |  |  | 45.7 |  | 196.2 |  | 241.9 |
Revenue | $ | 8,489.4 |  | $ | 4,239.1 |  | $ | 12,728.5 |  |  | $ | 5,694.4 |  | $ | 3,073.7 |  | $ | 8,768.0 |
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. The following table summarizes revenue by geographical area:
| Three Months Ended March 31, |  |
| 2025 |  | 2024 |  |  |  |
Revenue(1): |  |  |  |  |  |  |
U.S. | $ | 8,489.4 |  |  | $ | 5,694.4 |  |  |  |  |
Europe | 2,388.7 |  |  | 1,440.7 |  |  |  |  |
China | 450.8 |  |  | 376.2 |  |  |  |  |
Japan | 402.2 |  |  | 363.9 |  |  |  |  |
Rest of world | 997.4 |  |  | 892.9 |  |  |  |  |
Revenue | $ | 12,728.5 |  |  | $ | 8,768.0 |  |  |  |  |
(1) Revenue is attributed to the countries based on the location of the customer or other party.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration